Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn: Possible teratogenic effect
暂无分享,去创建一个
[1] G. S. Ang,et al. Mycophenolate mofetil embryopathy may be dose and timing dependent , 2008, American journal of medical genetics. Part A.
[2] J. F. Baumgratz,et al. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. , 2008, Transplantation.
[3] J. Carey,et al. Mycophenolate Mofetil During Pregnancy: Some Words of Caution , 2008, Pediatrics.
[4] J. Carey. "Where observation is concerned, chance favors only the prepared mind". , 2008, Obstetrics and gynecology.
[5] H. Rehder,et al. Severe Facial Clefts in Acrofacial Dysostosis: A Consequence of Prenatal Exposure to Mycophenolate Mofetil? , 2008, Obstetrics and gynecology.
[6] R. Snanoudj,et al. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] Serban Constantinescu,et al. Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus , 2006, Transplantation.
[8] S. Ceylaner,et al. A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect , 2006, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[9] K. Jones,et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy , 2005, American journal of medical genetics. Part A.
[10] R. Frydman,et al. Mycophenolate Mofetil in Pregnancy After Renal Transplantation: A Case of Major Fetal Malformations , 2004, Obstetrics and gynecology.
[11] M. Moritz,et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. , 2003, Clinical transplants.
[12] D. Riley,et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. , 2001, Transplantation.
[13] E A Harvey,et al. The teratogenicity of anticonvulsant drugs. , 2001, The New England journal of medicine.
[14] L. Garrison,et al. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1997, Journal of the American Society of Nephrology : JASN.
[15] Sollinger Hw. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .
[16] P Fauchald,et al. PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .
[17] J. Opitz,et al. Teratogenicity of anticonvulsant drugs. , 1985, American journal of medical genetics.
[18] A. Ledo,et al. In utero exposure to mycophenolate mofetil: A characteristic phenotype? , 2008, American journal of medical genetics. Part A.
[19] M. Velinov,et al. The fetal mycophenolate mofetil syndrome. , 2008, Clinical dysmorphology.
[20] D. Bastiaans,et al. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use , 2007, Journal of Perinatology.
[21] M. Moritz,et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. , 2002, Clinical transplants.